News – Alligator Bioscience

2019-12-17

Alligator Bioscience: First patient dosed with ATOR-1017 developed for metastasized cancer

Lund, Sweden, December 17, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that the first patient has been successful ...

2019-12-11

Lund, Sweden, December 11, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that CFO (Chief Financial Officer) Per-Olo ...

2019-11-29

Lund, November 29, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX today announced that the company has appointed Dr Malin Carlsson as ...

2019-11-13

Lund, Sweden, November 13, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmace ...

2019-11-08

Preclinical Data Show that ALG.APV-527 is Well Tolerated with Repeated Dosing Preliminary in vivo Data Show that ALG.APV-527 has Potent Anti ...

2019-11-06

Lund, Sweden, November 6, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that the company will present new preclinic ...

2019-10-24

Regulatory

"We are now regaining the exclusive, global rights to develop and commercialize ADC-1013 and at the same time receive enough ADC-1013 su ...

2019-08-20

Regulatory

Lund, Sweden, August 20, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that a license agreement has been reached wi ...

2019-07-31

Regulatory

Lund, Sweden, July 31, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that it has regained exclusive, worldwide righ ...